Key Dates

Related Announcements

•  March 16, 2023 - NHLBI Notice of Clarification and Availability of Frequently Asked Questions (FAQs) for RFA-HL-23-008 and RFA-HL-23-009 "NHLBI SBIR Phase IIB Small Market Awards." See Notice NOT-HL-23-082.

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to rescind NOT-HL-23-082 “NHLBI Notice of Clarification and Availability of Frequently Asked Questions (FAQs) for RFA-HL-23-008 and RFA-HL-23-009 NHLBI SBIR Phase IIB Small Market Awards," effective immediately.

Due to a change in policy outlined in the new Commercialization Readiness Pilot Program NOFOs (PAR-23-219 and PAR-23-220), the NIH will accept Phase IIB and CRP applications for the same Phase II project concurrently, i.e., Phase IIB and CRP applications for the same Phase II project may be under review at the same time if they are scientifically distinct. The NIH SEED FAQ page has been updated accordingly to reflect this policy change. 

Potential applicants may continue to consider submitting applications to RFA-HL-23-008 NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) and RFA-HL-23-009 NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional). 

All related FAQs are available online at the following link: Frequently Asked Questions (FAQs) | Seed (nih.gov). Applicants are strongly encouraged to review the FAQs, which may be updated at any time without additional notice, prior to submitting their application.

Inquiries

Please direct all inquiries to:

NHLBI Innovation and Commercialization (I&C) Office
Email: nhlbi_sbir@mail.nih.gov